Issues and Practices in Multiple Sclerosis

Neurorehabilitation and Neural Repair

Volumn 16, Issue 4, 2002, Pages 307-320

  Burks, Jack S ^a   Arnason, Barry G ^b   Coyle, Patricia K ^c   Ford, Corey C ^d   Noronha, Avertano ^e   Rammohan, Kottil W ^f  

^a University of Nevada School of Medicine   (United States)

^b UNIVERSITY OF CHICAGO   (United States)

^c STONY BROOK UNIVERSITY   (United States)

^d UNIVERSITY OF NEW MEXICO HEALTH SCIENCES CENTER   (United States)

^e UNIVERSITY OF CHICAGO   (United States)

^f OHIO STATE UNIVERSITY   (United States)

Author keywords

Adverse effects; Brain atrophy; Glatiramer acetate; Imunotherapy; Interferon ?; Magnetic resonance imaging; Mitoxantrone; Multiple sclerosis

Indexed keywords

ALPHA INTERFERON; ANTIDEPRESSANT AGENT; BETA1A INTERFERON; BIOLOGICAL MARKER; GLATIRAMER; INTERFERON BETA SERINE; MITOXANTRONE; MYXOVIRUS RESISTANCE PROTEIN; NONSTEROID ANTIINFLAMMATORY AGENT; PREDNISONE; UNCLASSIFIED DRUG;

BRAIN ATROPHY; CARDIOTOXICITY; CLINICAL FEATURE; CLINICAL TRIAL; DEPRESSION; DIAGNOSTIC IMAGING; DISEASE CLASSIFICATION; DRUG EFFICACY; FLU LIKE SYNDROME; GENETIC ASSOCIATION; HEADACHE; HUMAN; IMMUNOTHERAPY; INJECTION SITE; MULTIPLE SCLEROSIS; NUCLEAR MAGNETIC RESONANCE IMAGING; PATIENT CARE; RELAPSE; REVIEW; SIDE EFFECT; SKIN ULCER; TREATMENT OUTCOME; TREATMENT PLANNING;

ADJUVANTS, IMMUNOLOGIC; ANTINEOPLASTIC AGENTS; COMBINED MODALITY THERAPY; FORECASTING; HUMANS; IMMUNOTHERAPY; MAGNETIC RESONANCE IMAGING; MITOXANTRONE; MULTIPLE SCLEROSIS; PRACTICE GUIDELINES;

EID: 0036891530     PISSN: 15459683     EISSN: None     Source Type: Journal    
DOI: 10.1177/154596830201600401     Document Type: Article

References (95)

1. Weinshenker BG, Bass B, Rice GPA, et al. The natural history of multiple sclerosis: a geographically based study, I: clinical course and disability. Brain 1989; 112: 133-146.
2. Lublin FD, Reingold SC, for the National Multiple Sclerosis Society (USA) Advisor Committee on Clinical Trials of New Agents in Multiple Sclerosis. Defining the course of multiple sclerosis: results of an international survey. Neurology 1996; 46: 907-911.
3. Weinshenker BG. The natural history of multiple sclerosis. Neurol Clin 1995; 13(1):119-146.
4. Andersson PB, Waubant E, Gee L, Goodkin DE. Multiple sclerosis that is progressive from the time of onset. Arch Neurol 1999; 56: 1138-1142.
5. Scott TF, Schramke CJ, Novero J, Chieffe C. Short-term prognosis in early relapsing-remitting multiple sclerosis. Neurology 2000; 55: 689-693.
6. Weinshenker BG, Rice GPA, Noseworthy JH, Carriere W, Baskerville J, Ebers GC. The natural history of multiple sclerosis: a geographically based study. Brain 1991; 114: 1045-1056.
7. Kantarei O, Siva A, Eraksoy M, et al., and the Turkish Multiple Sclerosis Study Group (TUMSSG). Survival and predictors of disability in Turkish MS patients. Neurology 1998; 51: 765-772.
8. Lycklama à Nijeholt GJ, van Walderveen MAA, Castelijns JA, et al. Brain and spinal cord abnormalities in multiple sclerosis. Correlation between MRI parameters, clinical sub-types and symptoms. Brain 1998; 121: 687-697.
9. Thorpe JW, Kidd D, Moseley IF, et al. Serial gadolinium-enhanced MRI of the brain and spinal cord in early relapsing-remitting multiple sclerosis. Neurology 1996; 46: 373-378.
10. Thompson AJ, Kermode AG, MacManus DG, et al. Patterns of disease activity in multiple sclerosis: clinical and magnetic resonance imaging study. BMJ 1990; 300: 631-634.
11. Kidd D, Thorpe JW, Kendall BE, et al. MRI dynamics of brain and spinal cord in progressive multiple sclerosis. J Neurol Neurosurg Psychiatry 1996; 60(1):15-19.
12. Tubridy N, Coles AJ, Molyneux P, et al. Secondary progressive multiple sclerosis: the relationship between short-term MRI activity and clinical features. Brain 1998; 121: 225-231.
13. Thompson AJ, Kermode AG, Wicks D, et al. Major differences in the dynamics of primary and secondary progressive multiple sclerosis. Ann Neurol 1991; 29(1):53-62.
14. Thompson AJ, Polman CH, Miller DH, et al. Primary progressive multiple sclerosis (review). Brain 1997; 120: 1085-1096.
15. Bashir K, Whitaker JN. Clinical and laboratory features of primary and secondary progressive MS. Neurology 1999; 53: 765-771.
16. Durán I, Martínez-Cáceres EM, Río J, Barberà N, Marzo ME, Montalban X. Immunological profile of patients with primary progressive multiple sclerosis. Expression of adhesion molecules. Brain 1999; 122: 2297-2307.
17. Lucchinetti C, Brück W, Parisi J, Scheithauer B, Rodriguez M, Lassmann H. A quantitative analysis of oligodendrocytes in multiple sclerosis lesions. A study of 113 cases. Brain 1999; 122: 2279-2295.
18. Lucchinetti C, Brück W, Parisi J, Scheithauer B, Rodriguez M, Lassmann H. Heterogeneity of multiple sclerosis lesions: implications for the pathogenesis of demyelination. Ann Neurol 2000; 47: 707-717.
19. Trapp BD, Peterson J, Ransohoff RM, Rudick R, Mörk S, Bö L. Axonal transection in the lesions of multiple sclerosis. N Engl J Med 1998; 338: 278-285.
20. Trapp BD, Bö L, Mörk S, Chang A. Pathogenesis of tissue injury in MS lesions. J Neuroimmunol 1999; 98: 49-56.
21. Hawkins SA, McDonnell GV. Benign multiple sclerosis? Clinical course, long term follow up, and assessment of prognostic factors. J Neurol Neurosurg Psychiatry 1999; 67: 148-152.
22. Paty DW, McFarland H. Magnetic resonance techniques to monitor the long term evolution of multiple sclerosis pathology and to monitor definitive clinical trials. J Neurol Neurosurg Psychiatry 1998; 64(Suppl 1):S47-S51.
23. Compston A. The genetic epidemiology of multiple sclerosis. Philos Trans R Soc Lond B: Biol Sci 1999; 354: 1623-1634.
24. Kalman B, Lublin FD. The genetics of multiple sclerosis. A review. Biomed Pharmacother 1999; 53: 358-370.
25. Ebers GC, Koopman WJ, Hader W, et al. The natural history of multiple sclerosis: a geographically based study. 8: familial multiple sclerosis. Brain 2000; 123: 641-649.
26. Elian M, Dean G. Multiple sclerosis among the United Kingdom-born children of immigrants from the West Indies. J Neurol Neurosurg Psychiatry 1987; 50: 327-332.
27. Benedikz J, Magnússon H, Guthmundsson G. Multiple sclerosis in Iceland, with observations on the alleged epidemic in the Faroe Islands. Ann Neurol 1994; 36(Suppl 2):S175-S179.
28. Acers TE, Acers-Warn A. Incidence patterns of immunogenetic diseases in the North American Indians. J Okla State Med Assoc 1994; 87: 309-314.
29. Ross RT, Nicolle LE, Cheang M. Varicella zoster virus and multiple sclerosis in a Hutterite population. J Clin Epidemiol 1995; 48(11):1319-1324.
30. Cook SD, Rohowsky-Kochan C, Bansil S, Dowling PC. Evidence for a viral etiology of multiple sclerosis. In: Cook SD, editor. Handbook of multiple sclerosis. 2nd ed. New York: Marcel Dekker, 1996. chap. 4.
31. Friedman JE, Lyons MJ, Cu G, et al. The association of the human herpesvirus-6 and MS. Mult Scler 1999; 5: 355-362.
32. Sriram S, Stratton CW, Yao SY, et al. Chlamydia pneumoniae infection of the central nervous system in multiple sclerosis. Ann Neurol 1999; 46: 6-14.
33. Sriram S, Mitchell W, Stratton C. Multiple sclerosis associated with Chlamydia pneumoniae infection of the CNS. Neurology 1998; 50: 571-572.
34. Kim S, Liva SM, Dalal MA, Verity MA, Voskuhl RR. Estriol ameliorates autoimmune demyelinating disease. Implications for multiple sclerosis. Neurology 1999; 52: 1230-1238.
35. Confraveux C, Hutchinson M, Hours MM, Cortinovis-Tourniaire P, Moreau T, and the Pregnancy in Multiple Sclerosis Group. Rate of pregnancy-related relapse in multiple sclerosis. N Engl J Med 1998; 339(5):285-291.
36. Fazekas F, Barkhof F, Filippi M, et al. The contribution of magnetic resonance imaging to the diagnosis of multiple sclerosis. Neurology 1999; 53: 448-456.
37. Losseff NA, Wang L, Lai HM, et al. Progressive cerebral atrophy in multiple sclerosis. A serial MRI study. Brain 1996; 119: 2009-2019.
38. Liu C, Edwards S, Gong Q, Roberts N, Blumhardt LD. Three-dimensional MRI estimates of brain and spinal cord atrophy in multiple sclerosis. J Neurol Neurosurg Psychiatry 1999; 66: 323-330.
39. Stevenson VL, Leary SM, Losseff NA, et al. Spinal cord atrophy and disability in MS. A longitudinal study. Neurology 1998; 51: 234-238.
40. Simon JH, Jacobs LD, Campion MK, et al, and the Multiple Sclerosis Collaborative Research Group (MSCRG). A longitudinal study of brain atrophy in relapsing multiple sclerosis. Neurology 1999; 53: 139-148.
41. Davie CA, Barker GJ, Webb S, et al. Persistent functional deficit in multiple sclerosis and autosomal dominant cerebellar ataxia is associated with axon loss. Brain 1995; 118: 1583-1592.
42. Edwards SGM, Gong QY, Liu C, et al. Infratentorial atrophy on magnetic resonance imaging and disability in multiple sclerosis. Brain 1999; 122: 291-301.
43. Dastidar P, Heinonen T, Lehtimäke T, et al. Volumes of brain atrophy and plaques correlated with neurological disability in secondary progressive multiple sclerosis. J Neurol Sci 1999; 165: 36-42.
44. Gur RC, Mozley PD, Resnick SM, et al. Gender differences in age effect on brain atrophy measured by magnetic resonance imaging. Proc Natl Acad Sci USA 1991; 88: 2845-2849.
45. Jagust WJ, Noseworthy JH. Brain atrophy as a surrogate marker in MS: faster, simpler, better? Neurology 2000; 54: 782-783.
46. Rudick RA, Fisher E, Lee J-C, Simon J, Jacobs L, and the Multiple Sclerosis Collaborative Research Group. Use of the brain parenchymal fraction to measure whole brain atrophy in relapsing-remitting MS. Neurology 1999; 53: 1698-1704.
47. Ge Y, Grossman RI, Udupa JK, et al. Glatiramer acetate (Copaxone) treatment in relapsing-remitting MS: quantitative MR assessment. Neurology 2000; 54: 813-817.
48. Tortorella C, Viti B, Bozzali M, et al. A magnetization transfer histogram study of normal-appearing brain tissue in MS. Neurology 2000; 54: 186-193.
49. Rovaris M, Horsfield MA, Filippi M. Correlations between magnetization transfer metrics and other magnetic resonance abnormalities in multiple sclerosis. Neurology 1999; 53(Suppl 3):S40-S45.
50. Bagley LJ, Grossman RI, McGowan JC. Magnetization transfer contrast: its utility as a technique and its application to central nervous system pathology. Neurology 1999; 53(Suppl 3):S49-S51.
51. Van Waesberghe JHTM, Barkhof F. Magnetization transfer imaging of the spinal cord and the optic nerve in patients with multiple sclerosis. Neurology 1999; 53(Suppl 3):S46-S48.
52. Cannella B, Hoban CJ, Gao Y-L, et al. The neuregulin, glial growth factor 2, diminishes autoimmune demyelination and enhances remyelination in a chronic relapsing model for multiple sclerosis. Proc Natl Acad Sci USA 1998; 95: 10100-10105.
53. Fassas A, Anagnostopoulos A, Kazis A, et al. Peripheral blood stem cell transplantation in the treatment of progressive multiple sclerosis: first results of a pilot study. Bone Marrow Transplant 1997; 20: 631-638.
54. Burt RK, Traynor AE, Cohen B, et al. T cell-depleted autologous hematopoietic stem cell transplantation for multiple sclerosis: report on the first three patients. Bone Marrow Transplant 1998; 21: 537-541.
55. Burt RK, Traynor AE, Pope R, et al. Treatment of autoimmune disease by intense immunosuppressive conditioning and autologous hematopoietic stem cell transplantation. Blood 1998; 92(10):3505-3514.
56. Learish RD, Brüstle O, Zhang S-C, Duncan ID. Intraventricular transplantation of oligodendrocyte progenitors into a fetal myelin mutant results in widespread formation of myelin. Ann Neurol 1999; 46: 716-722.
57. IFNB Multiple Sclerosis Study Group. Interferon beta-1b is effective in relapsing-remitting multiple sclerosis: I. Clinical results of a multicenter, randomized, double-blind, placebo-controlled trial. Neurology 1993; 43: 655-661.
58. Jacobs LD, Cookfair DL, Rudick RA, et al, and the Multiple Sclerosis Collaborative Research Group (MSCRG). Intramuscular interferon beta-1a for disease progression in relapsing multiple sclerosis. Ann Neurol 1996; 39: 285-294.
59. Johnson KP, Brooks BR, Cohen JA, et al, and the Copolymer 1 Multiple Sclerosis Study Group. Copolymer 1 reduces relapse rate and improves disability in relapsingremitting multiple sclerosis: results of a phase III multicenter, double-blind, placebo-controlled trial. Neurology 1995; 45: 1268-1276.
60. PRISMS (Prevention of Relapses and Disability by Interferon β-1a Subcutaneously in Multiple Sclerosis) Study Group. Randomised double-blind placebo-controlled study of interferon β-1a in relapsing/remitting multiple sclerosis. Lancet 1998; 352: 1498-1504.
61. European Study Group on Interferon β-1b in Secondary Progressive MS. Placebo-controlled multicentre randomised trial of interferon β-1b in treatment of secondary progressive multiple sclerosis. Lancet 1998; 352(9139): 1491-1497.
62. Goodkin DE, and the North American Study Group on Interferon beta-1b in Secondary Progressive MS. Interferon beta-1b in secondary progressive MS: clinical and MRI results of a 3-year randomized controlled trial. Paper presented at the Annual Meeting of the American Academy of Neurology, 1 May 2000, San Diego, California.
63. Secondary Progressive Efficacy Clinical Trial of Recombinant Interferon-beta-1a in MS (SPECTRIMS) Study Group. Clinical results. Neurology 2001; 56: 1496-1504.
64. Cohen JA, Goodman AD, Heidenreich FR. Results of IMPACT, a phase 3 trial of interferon beta-1a in secondary progressive multiple sclerosis [abstract]. Neurology 2001; 56: A148.
65. IFNB Multiple Sclerosis Study Group and the University of British Columbia MS/MRI Analysis Group. Interferon beta-1b in the treatment of multiple sclerosis: final outcome of the randomized controlled trial. Neurology 1995; 45: 1277-1285.
66. Paty DW, Li DKB, UBC MS/MRI Study Group, and the IFNB Multiple Sclerosis Study Group. Interferon beta-1b is effective in relapsing-remitting multiple sclerosis. II. MRI analysis results of a multicenter, randomized, double-blind, placebo-controlled trial. Neurology 1993; 43: 662-667.
67. Zhao GJ, Koopmans RA, Li DKB, Bedell L, Paty DW, the UBC MS/MRI Analysis Group, and the MS Study Group. Effect of interferon β-1b in MS. Assessment of annual accumulation of PD/T2 activity on MRI. Neurology 2000; 54: 200-206.
68. Johnson KP, Brooks BR, Cohen JA, et al., and the Copolymer 1 Multiple Sclerosis Study Group. Extended use of glatiramer acetate (Copaxone) is well tolerated and maintains its clinical effect on multiple sclerosis relapse rate and degree of disability. Neurology 1998; 50: 701-708.
69. Comi G, Filippi M, Wolinsky JS, and the European/Canadian Glatiramer Acetate Study Group. European/Canadian multicenter, double-blind, randomized, placebo-controlled study of the effects of glatiramer acetate on magnetic resonance imaging—measured disease activity and burden in patients with relapsing multiple sclerosis. Ann Neurol 2001; 49: 290-297.
70. McFarland HF. Comparative analysis of the outcome of two phase III studies of interferon beta-1b. Paper presented at the Annual Meeting of the American Academy of Neurology, 1 May 2000, San Diego, California.
71. The Once Weekly Interferon for MS Study Group (OWIMS). Evidence of interferon β-1a dose response in relapsing-remitting MS. The OWIMS study. Neurology 1999; 53: 679-686.
72. Durelli et al. Presentation at the 17th Congress of the European Committee for Treatment and Research in Multiple Sclerosis, September 2001, Dublin, Ireland.
73. Kracke A, von Wussow P, Al-Masri AN, Dalley G, Windhagen A, Heidenreich F. Mx proteins in blood leukocytes for monitoring interferon beta-1b therapy in patients with MS. Neurology 2000; 54: 193-199.
74. IFNB Multiple Sclerosis Study Group and the University of British Columbia MS/MRI Analysis Group. Neutralizing antibodies during treatment of multiple sclerosis with interferon beta-1b: experience during the first three years. Neurology 1996; 47: 889-894.
75. Kivisäkk P, Alm GV, Tian WZ, Matusevicius D, Fredrikson S, Link H. Neutralising and binding anti-interferon-β-1b (IFN-β-1b) antibodies during IFN-β-1b treatment of multiple sclerosis. Mult Scler 1997; 3: 184-190.
76. Rice GPA, Paszner B, Oger J, Lesaux J, Paty D, Ebers G. The evolution of neutralizing antibodies in multiple sclerosis patients treated with interferon β-1b. Neurology 1999; 52: 1277-1279.
77. Arnason BG, Dianzani F. Correlation of the appearance of anti-interferon antibodies during treatment and diminution of efficacy: summary of an international workshop on anti-interferon antibodies. J Interferon Cytokine Res 1998; 18: 639-644.
78. Cross AH, Antel JP. Antibodies to beta-interferons in multiple sclerosis. Can we neutralize the controversy? Neurology 1998; 50: 1206-1208.
79. Hadjimichael O, Vollmer TL. Adherence to injection therapy in multiple sclerosis: patients survey [abstract]. Neurology 1999; 52(Suppl 2):A549.
80. Comi G, Filippi M, for the Copaxone MRI Study Group. The effect of glatiramer acetate (Copaxone®) on disease activity as measured by cerebral MRI in patients with relapsing-remitting multiple sclerosis (RRMS): a multicenter, randomized, double-blind, placebo-controlled study extended by open-label treatment [abstract]. Neurology 1999; 52(Suppl 2):A289.
81. Krapf H, Morrissey SP, Zenker O, Gonsette R, Hartung HP, and the MIMS-Study Group. Mitoxantrone in progressive multiple sclerosis (MS): a placebo-controlled, randomized, observer-blind European phase III multicenter study-MRI results [abstract]. Mult Scler 1998; 4: 380.
82. Hartung H-P, Gonsette R, and the MIMS-Study Group. Mitoxantrone in progressive multiple sclerosis (MS): a placebo-controlled, randomized, observer-blind European phase III multicenter study-clinical results [abstract]. Mult Scler 1998; 4: 325.
83. De Castro S, Cartoni D, Millefiorini E, et al. Noninvasive assessment of mitoxantrone cardiotoxicity in relapsing remitting multiple sclerosis. J Clin Pharmacol 1995; 35: 627-632.
84. Walther EU, Hohlfeld R. Multiple sclerosis. Side effects of interferon beta therapy and their management. Neurology 1999; 53: 1622-1627.
85. Rice GPA, Ebers GC, Lublin FD, Knobler RL. Ibuprofen treatment versus gradual introduction of interferon β-1b in patients with MS. Neurology 1999; 52: 1893-1895.
86. Lublin FD, Whitaker JN, Eidelman BH, Miller AE, Arnason BGW, Burks JS. Management of patients receiving interferon beta-1b for multiple sclerosis: report of a consensus conference. Neurology 1996; 46: 12-18.
87. Brod SA, Lindsey JW, Wolinsky JS. Combination therapy with glatiramer acetate (copolymer-1) and a type I interferon (IFN-α) does not improve experimental autoimmune encephalomyelitis. Ann Neurol 2000; 47: 127-131.
88. Durelli L, Bongioanni MR, Cavallo R, et al. Chronic systemic high-dose recombinant interferon alfa-2a reduces exacerbation rate, MRI signs of disease activity, and lymphocyte interferon gamma production in relapsing-remitting multiple sclerosis. Neurology 1994; 44: 406-413.
89. Myhr KM, Riise T, Green Lilleås FE, et al. Interferon-α2a reduces MRI disease activity in relapsing-remitting multiple sclerosis. Neurology 1999; 52: 1049-1056.
90. Goodkin DE, Shulman M, Winkelhake J, et al. A phase I trial of solubilized DR2: MBP84-102 (AG284) in multiple sclerosis. Neurology 2000; 54: 1414-1420.
91. Suzumura A, Nakamuro T, Tamaru T, Takayanagi T. Drop in relapse rate of MS by combination therapy of three different phosphodiesterase inhibitors. Mult Scler 2000; 6(1):56-58.
92. Paolillo A, Coles AJ, Molyneux PD, et al. Quantitative MRI in patients with secondary progressive MS treated with monoclonal antibody Campath 1H. Neurology 1999; 53: 751-757.
93. Rudick R, Antel J, Confavreux C, et al. Recommendations from the National Multiple Sclerosis Society Clinical Outcomes Assessment Task Force. Ann Neurol 1997; 42: 379-382.
94. Sicotte N, Mattiello J, Sinha U, Klutch R, Voskuhl R, Alger J. Serial diffusion tensor imaging in patients with multiple sclerosis [abstract]. Mult Scler 1999; 5(Suppl 1):S20.
95. Barkhof F. Black holes clinicopathological correlation; MRI markers for axonal loss [abstract]. Mult Scler 1999; 5(Suppl 1):S8.